Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 23 of 23 entries
View as:

Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03392168 Org: User:
Start: 12/11/17 End: 05/02/18 Due: 05/02/19

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03638258 Org: User:
Start: 09/21/18 End: 05/29/19 Due: 05/29/20

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04804605 Org: User:
Start: 02/25/21 End: 05/28/24 Due: 05/28/25

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04128007 Org: User:
Start: 01/13/20 End: 09/25/20 Due: 09/25/21

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04773587 Org: User:
Start: 01/27/21 End: 08/30/22 Due: 08/30/23

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Phase: N/A Priority: Normal
NCT ID: NCT04973228 Org: User:
Start: 07/08/21 End: 04/06/22 Due: 04/06/23

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Phase: N/A Priority: Normal
NCT ID: NCT05028582 Org: User:
Start: 08/24/21 End: 06/03/22 Due: 06/03/23

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04091646 Org: User:
Start: 12/04/19 End: 08/21/20 Due: 08/21/21

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

Phase: N/A Priority: Normal
NCT ID: NCT04156191 Org: User:
Start: 12/23/19 End: 05/02/23 Due: 05/02/24

Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04211363 Org: User:
Start: 12/20/19 End: 11/16/20 Due: 11/16/21

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03916081 Org: User:
Start: 05/31/19 End: 11/04/19 Due: 11/04/20

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06998056 Org: User:
Start: 06/09/25 End: 06/30/26 Due: 06/30/27

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04211389 Org: User:
Start: 12/17/19 End: 11/23/20 Due: 11/23/21

Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03764475 Org: User:
Start: 12/18/18 End: 10/08/20 Due: 10/08/21

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Phase: N/A Priority: Normal
NCT ID: NCT04378569 Org: User:
Start: 04/20/20 End: 02/24/21 Due: 02/24/22

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Phase: N/A Priority: Normal
NCT ID: NCT04811131 Org: User:
Start: 03/04/21 End: 08/09/21 Due: 08/09/22

Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04445987 Org: User:
Start: 06/12/20 End: 11/19/22 Due: 11/19/23

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Phase: N/A Priority: Normal
NCT ID: NCT04655313 Org: User:
Start: 11/30/20 End: 01/12/22 Due: 01/12/23

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04286607 Org: User:
Start: 02/12/20 End: 01/22/24 Due: 01/22/25

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04279119 Org: User:
Start: 03/10/20 End: 03/25/21 Due: 03/25/22

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Phase: N/A Priority: Normal
NCT ID: NCT04845620 Org: User:
Start: 04/07/21 End: 06/01/23 Due: 06/01/24

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Phase: N/A Priority: Normal
NCT ID: NCT04746911 Org: User:
Start: 03/01/21 End: 05/11/22 Due: 05/11/23

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Phase: N/A Priority: Normal
NCT ID: NCT04773600 Org: User:
Start: 02/24/21 End: 09/29/22 Due: 09/29/23